XML 31 R25.htm IDEA: XBRL DOCUMENT v3.24.3

Revenue Recognition (Tables)

9 Months Ended

Sep. 30, 2024

Revenue from Contract with Customer [Abstract]

Schedule of net revenue from collaboration arrangement

Net revenue recognized under our GSK Agreements was as follows:

		Three Months Ended September 30,								Nine Months Ended September 30,
(In thousands)		2024				2023				2024				2023
Royalties    - RELVAR/BREO		$	48,199			$	45,585			$	154,317			$	150,922
Royalties    - ANORO			12,313				11,429				35,264				32,127
Total royalties			60,512				57,014				189,581				183,049
Less: amortization of capitalized fees paid			(3,456	)			(3,456	)			(10,368	)			(10,368	)
Total net royalty revenue		$	57,056			$	53,558			$	179,213			$	172,681

X

- Definition

Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-5

+ Details

Name:	us-gaap_DisaggregationOfRevenueTableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- References

No definition available.

+ Details

Name:	us-gaap_RevenueFromContractWithCustomerAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration